

### REMARKS

Claims 1-47 were originally filed in this application. In the Preliminary Amendment filed on November 21, 2003, claims 30-34 and 36-40 were cancelled without prejudice to Applicants' right to pursue the subject matter of the cancelled claims in related applications.


Claims 1-13, 15, 19-40, 46 and 47 have been cancelled without prejudice to Applicants' right to pursue the subject matter of the cancelled claims in related applications. Claims 14 and 43 have been amended to recite that the anti-C3b(i) antibody is conjugated to a therapeutic agent. Support for claims 14 and 43 can be found in the specification at, *inter alia*, page 8, lines 15-18; page 26, lines 32-34; and cancelled claim 19. Claims 16 and 17 have been amended to reflect cancelled claim 15. Claim 18 has been rewritten as a dependent claim of claim 14. New claims 48-55 have been added to more clearly point out and distinctly claim the subject matter of certain embodiments of the present invention. Specifically, new dependent claim 48 relates to antibodies that are monoclonal antibodies. Support for new claim 48 can be found in the specification at, *inter alia*, page 8, lines 6-7; page 15, line 20. New dependent claim 49 relates to antibodies that are humanized. Support for new claim 49 can be found in the specification at, *inter alia*, page 8, lines 6-7; page 15, lines 20-21. New dependent claim 50 recites that the therapeutic agent conjugated to the anti-C3b(i) antibody can be a radioactive agent. Support for new claim 50 can be found in the specification at, *inter alia*, page 8, lines 15-18; and page 26, lines 32-34. New dependent claim 51 recites that the therapeutic agent conjugated to the anti-C3b(i) antibody can be a cytotoxin. Support for new claim 51 can be found in the specification at, *inter alia*, page 8, lines 15-16; page 26, lines 32-33. New dependent claim 52 recites a number of therapeutic agents to which the anti-C3b(i) antibody can be conjugated. Support for new claim 52 can be found in the specification at, *inter alia*, page 26, line 34 to page 27, line 4. New dependent claim 53 recites that the therapeutic agent conjugated to the anti-C3b(i) antibody can be cobra venom factor. Support for new claim 53 can be found in the specification at, *inter alia*, page 27, lines 13-16. New dependent claim 54 recites that the therapeutic agent conjugated to the anti-C3b(i) antibody can be abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin. Support for new claim 54 can be found in the specification at, *inter alia*, page 27, lines 13-22. New dependent claim 55 relates to pharmaceutical composition comprising purified anti-C3b(i) antibodies. Support for new claim 55 can be found in the specification at, *inter alia*, page 26, lines 7-12. No new matter has been added.

Upon entry of this amendment, claims 14, 16-18, 41-45 and 48-55 will be pending in the present application.

Entry of the foregoing amendments and consideration of the foregoing remarks are respectfully requested.

Respectfully submitted,

Date: July 9, 2004

  
\_\_\_\_\_  
Geraldine F. Baldwin 31,232  
(Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939